District Court, E.D. Pennsylvania January 21, 2010, Civil Action 08-CV-3301 (In Re Flonase Antitrust Litigation)

Also known as

United States · · · 21-01-2010

MEMORANDUM

ANITA B. BRODY, District Judge.

I. Introduction

On May 21, 2009, Plaintiffs A.F. of L.A.G.C. Building Trades Welfare Plan (“AFL”), International Association of Bridge, Structural, Ornamental and Reinforcing Ironworkers Local No. 79 Health Fund (“IABORI”), IBEW-NECA Local 505 Health and Welfare Plan (“IBEW”), Painters District Council No. 30 Health & Welfare Fund (“Painters”), Sheet Metal Workers Local 441 Health and Welfare Plan (“Sheet Metal”), and Andrea Kehoe (“Kehoe”), collectively “Plaintiffs,” filed a corrected second amended class action complaint (“SAC”) against Defendant SmithKline Beecham Corporation, doing business as GlaxoSmithKline, Inc. (“GSK”).

Plaintiffs are indirect purchasers of the prescription drug Flonase. They allege that GSK filed sham citizen petitions with the Food and Drug Administration (“FDA”) to delay the entry of a generic version of Flonase (fluticasone propionate)

1

into the market. Plaintiffs bring claims against GSK under several states’ laws: (1) Monopolization under the law of Arizona, Iowa, North Carolina, and Wisconsin; (2) Unfair and Deceptive Trade Practices under the law of Arizona, Florida, Illinois, Iowa, Massachusetts and North Carolina; and (3) Unjust Enrichment under the law of Arizona, Florida, Illinois, Iowa, Massachusetts, North Carolina, and Wisconsin. Plaintiffs maintain that they sustained injury when they “purchased and/or provided reimbursement for Flonase purchases” in the respective states. (Compl. ¶¶ 5-9.) On June 19, 2009, GSK filed a Motion to Dismiss the second amended complaint.

II. Background

2

Under the Federal Food, Drug and Cosmetic Act (“FDCA”), drug manufacturers must receive FDA approval before selling a new drug. The manufacturer of a new drug who obtains FDA approval enjoys a period of market exclusivity during which their patent is protected. Once this period expires, other (“generic”) manufacturers may market and sell the drug.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.